Barclays Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $180
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Carter Gould maintains an Overweight rating on Neurocrine Biosciences (NASDAQ:NBIX) and raises the price target from $169 to $180.
August 02, 2024 | 3:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays analyst Carter Gould maintains an Overweight rating on Neurocrine Biosciences and raises the price target from $169 to $180.
The Overweight rating and increased price target from a reputable analyst at Barclays is likely to positively influence investor sentiment and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100